These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29289641)

  • 1. Medication coverage for lawmakers may worsen access for everyone else.
    Taglione MS; Boozary A; Persaud N
    Prev Med; 2018 Mar; 108():67-73. PubMed ID: 29289641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated cost of universal public coverage of prescription drugs in Canada.
    Morgan SG; Law M; Daw JR; Abraham L; Martin D
    CMAJ; 2015 Apr; 187(7):491-497. PubMed ID: 25780047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
    Morgan SG; Li W; Yau B; Persaud N
    CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.
    Daw JR; Morgan SG
    Health Policy; 2012 Jan; 104(1):19-26. PubMed ID: 21978939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Universal Pharmacare in Canada: A Prescription for Equity in Healthcare.
    Hajizadeh M; Edmonds S
    Int J Health Policy Manag; 2020 Mar; 9(3):91-95. PubMed ID: 32202091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canadian Health Care System: Who Should Pay for All Medically Beneficial Treatments? A Burning Issue.
    Chowdhury MZI; Chowdhury MA
    Int J Health Serv; 2018 Apr; 48(2):289-301. PubMed ID: 29095077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2018 decision to establish an Advisory Council on adding pharmaceuticals to universal health coverage in Canada.
    Grignon M; Longo CJ; Marchildon GP; Officer S
    Health Policy; 2020 Jan; 124(1):7-11. PubMed ID: 31761273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Universal prescription drug coverage in Canada: Long-promised yet undelivered.
    Morgan SG; Boothe K
    Healthc Manage Forum; 2016 Nov; 29(6):247-254. PubMed ID: 27744279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An American approach to health system reform.
    Holahan J; Moon M; Welch WP; Zuckerman S
    JAMA; 1991 May; 265(19):2537-40. PubMed ID: 2020072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing horizontal equity in medication treatment among elderly Mexicans: which socioeconomic determinants matter most?
    Maurer J
    Health Econ; 2008 Oct; 17(10):1153-69. PubMed ID: 18074405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the Battle for Universal Pharmacare in Canada Comment on "Universal Pharmacare in Canada".
    Gagnon MA
    Int J Health Policy Manag; 2021 Mar; 10(3):168-171. PubMed ID: 32610789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.
    Brandt J; Shearer B; Morgan SG
    J Pharm Policy Pract; 2018; 11():28. PubMed ID: 30443371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription drug coverage among elderly and disabled Americans: can Medicare-Part D reduce inequities in access?
    Kanavos P; Gemmill-Toyama M
    Int J Health Care Finance Econ; 2010 Sep; 10(3):203-18. PubMed ID: 20213234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insurance coverage and the treatment of mental illness: effect on medication and provider use.
    Mulvale G; Hurley J
    J Ment Health Policy Econ; 2008 Dec; 11(4):177-99. PubMed ID: 19096092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disability in two health care systems: access, quality, satisfaction, and physician contacts among working-age Canadians and Americans with disabilities.
    Gulley SP; Altman BM
    Disabil Health J; 2008 Oct; 1(4):196-208. PubMed ID: 21122730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries.
    Kennedy J; Morgan S
    Clin Ther; 2009 Jan; 31(1):213-9. PubMed ID: 19243719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Envisioning a Better U.S. Health Care System for All: Coverage and Cost of Care.
    Crowley R; Daniel H; Cooney TG; Engel LS;
    Ann Intern Med; 2020 Jan; 172(2 Suppl):S7-S32. PubMed ID: 31958805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Socioeconomic differences in prescription drug supplemental coverage in Canada: A repeated cross-sectional study.
    Guo EX; Sweetman A; Guindon GE
    Health Policy; 2020 Mar; 124(3):252-260. PubMed ID: 31952864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription Drug Priorities under the Biden Administration.
    Gavulic KA; Dusetzina SB
    J Health Polit Policy Law; 2021 Aug; 46(4):599-609. PubMed ID: 33503239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.